共 50 条
- [21] High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastomaPEDIATRIC BLOOD & CANCER, 2023, 70 (07)Kobushi, HirokazuSaida, SatoshiUmeda, KatsutsuguIwai, AtsushiKozuki, KagehiroKubota, HirohitoTanaka, KuniakiObu, SatoshiUchihara, YoshinoriTasaka, KeijiKato, ItaruHiramatsu, HidefumiTakita, Junko
- [22] Temozolomide versus Irinotecan-Temozolomide for Children with Relapsed and or Refractory High-Risk Neuroblastoma (RR-HRNB). Results of the Beacon-Neuroblastoma Randomized Phase II Trial, an ITCC-SIOPEN TrialPEDIATRIC BLOOD & CANCER, 2019, 66 : S34 - S34Moreno, L.Moroz, V.Owens, C.Valteau-Couanet, D.Gambart, M.van Eijkelenburg, N.Zwaan, C. M.Castel, V.Murphy, D.Morland, B.Gray, J.Marshall, L.Burchill, S.Chesler, L.Peet, A.Schleiermacher, G.Fenwick, N.Kearns, P.Pearson, A.Wheatley, K.
- [23] Phase I study of oral irinotecan and temozolomide in children with relapsed high-risk neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium studyJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Wagner, L. M.Villablanca, J. G.Stewart, C. F.Crews, K. R.O'Shaughnessy, M. A.Groshen, S.Reynolds, C. P.Park, J. R.Maris, J. M.Matthay, K. K.
- [24] Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse eventsCANCER REPORTS, 2023, 6 (01)Mora, JaumeChan, Godfrey C.Morgenstern, Daniel A.Nysom, KarstenBear, Melissa K.Tornoe, KarenKushner, Brian H.
- [25] Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children's Hospital of Fudan UniversityDRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 115 - 123Qian, XiaowenZhang, DufeiLi, KaiChen, WeimingZhuang, PeijunWang, HongshengLei, ZhixianLi, YanEldridge, JamesDong, KuiranZhai, Xiaowen
- [26] Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Corbacioglu, SelimLode, Holger N.Jakob, MarcusSuttorp, MeinolfEscherich, GabrieleGruhn, BerndEllinger, SusanneSimon, ThorstenLang, PeterRohde, MariusZeman, FlorianDebatin, Klaus-MichaelBeilken, AndreasHeiss, PeterHellwig, DirkRiemenschneider, MarkusLadenstein, Ruth LydiaBochennek, KonradEggert, AngelikaFoell, Juergen
- [27] Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HRNB): Response data and efficacy in patient (pt) subgroups.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Mora, JaumeChan, Godfrey Chi-FungMorgenstern, Daniel A.Nysom, KarstenBear, MelissaTornoe, KarenSorensen, Per SettergrenKushner, Brian H.
- [28] NEW TREATMENTS, NEW CHALLENGES: NEPHROTOXICITY ASSOCIATED WITH NAXITAMAB IN HIGH-RISK NEUROBLASTOMA PATIENTSPEDIATRIC BLOOD & CANCER, 2023, 70Gorostegui, MaiteMunoz-Perez, Juan PabloAguilar-Rodriguez, Ana CristinaSancho, Pedro ArangoIzurieta, Ana CarolinaMora, Jaume
- [29] New treatments, new challenges: nephrotoxicity associated to naxitamab in patients with high-risk neuroblastomaNEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1857 - I1857Arango Sancho, PedroAguilar Rodriguez, Ana CristinaLopez Espinoza, YarimaFortes Marin, EmmaMunoz Perez, Juan PabloGorostegui Obanos, MaiteCalzada Banos, YolandaLopez Baez, Victor AlfonsoJimenez Moreno, MartaCodina Sampera, ElenaMadrid Aris, AlvaroMora, Jaume
- [30] NEW TREATMENTS, NEW CHALLENGES: NEPHROTOXICITY ASSOCIATED TO NAXITAMAB IN PATIENTS WITH HIGH-RISK NEUROBLASTOMAPEDIATRIC NEPHROLOGY, 2023, 38 : S104 - S105Aguilar Rodriguez, Ana CristinaArango Sancho, PedroMunoz Perez, Juan PabloGorostegui Obanos, MaiteIzurieta Pacheco, Ana CarolinaCodina Sampera, ElenaJimenez Moreno, MartaCalzada Banos, YolandaJimenez Garcia, RaquelGomez Herrera, BernatMadrid Aris, AlvaroMora, Jaume